KAKKIS EMIL D

CEO Emil Kakkis sold 54.4K RARE shares at $22.80; stock down 39.4% in 90 days, mirroring his well-timed prior sales pattern at the ticker.

Emil Kakkis, President & CEO of Ultragenyx (RARE), sold 54,404 shares on 2026-03-02 at $22.80, reducing his stake by 7.6% to 658,994 shares. At the transaction price, this represented $1,240,411.20 in realized proceeds. The stock has since declined 39.4% over 90 days and is trading 48.6% below its 52-week high of $42.92. His prior five sales at RARE show a strong pattern of well-timed exits: 4 of 5 earlier sells were followed by negative 90-day returns, with the most recent two sales (2025-03-03 and 2025-02-28) both preceded declines of -19.2% and -17.5% respectively in the following 90 days. The company remains unprofitable on a full-year basis, with net income of $-180,413,000.00 despite quarterly revenue of $159,933,000.00 and annual growth of 20.1%, suggesting the CEO's divestiture occurs during continued operational losses and stock-price deterioration.

CEO Kakkis sells 98,434 shares (98.4K) for $4,153,571.40 via 2 transactions at blended avg $42.20

Emil Kakkis, President & CEO of Ultragenyx Pharmaceutical, executed 2 separate sales totaling 98,434 shares for $4,153,571.40, reducing his stake from 2,257,419 to 2,158,985 shares (-4.4%). The sales occurred on 2025-02-28 and 2025-03-03 at an average price of $42.20, compared to the current price of $41.10 (down 30.8% from the 52-week high of $59.36). At the same ticker, Kakkis's 5 prior sales yielded 3 instances of negative 90-day returns, indicating 60% of his prior RARE sells were well-timed before subsequent declines. Given the company's unprofitable status (net income of $-133,516,000 for the latest quarter) despite 29.0% annual revenue growth, insider selling activity warrants attention to whether this signals perception of near-term headwinds or valuation concerns relative to the current price momentum.

CEO Kakkis sold 20,000 shares (20.0K shares) of RARE at $55.85 on 2024-09-03 ($1.1M); holds 2.22M shares post-sale.

KAKKIS EMIL D, President & CEO of Ultragenyx Pharmaceutical Inc., sold 20,000 shares at $55.85, representing a 0.9% reduction from his 2.24M share position. The sale occurred as the stock had appreciated significantly (30-day change +13.4%, 90-day change +36.4%), positioning it near its 52-week high of $57.79. Across his prior 4 sales at RARE, timing has been mixed: 2 of 3 measurable outcomes showed well-timed exits (negative 90-day returns post-sale), but his most recent RARE sale on 2024-08-06 was followed by sustained strength (+12.5% in 30 days). The company remains unprofitable with $-131.6M in net income for the latest full fiscal year, though it posted $147.0M in quarterly revenue and 19.5% annual revenue growth. This sale merits attention as a data point within a pattern of recent CEO liquidations at this ticker.

Ultragenyx CEO KAKKIS EMIL D sold 20,000 shares ($1.0M) on 2024-08-06 at $50.17; stock now at $48.94

On 2024-08-06, KAKKIS EMIL D, President & CEO of Ultragenyx Pharmaceutical Inc., sold 20,000 shares at $50.17 for $1,003,400.00, reducing his holdings from 2,263,985 shares to 2,243,985 shares (a -0.9% reduction). The sale occurred when the stock was trading near its 52-week high ($53.69), and subsequent price action has been mixed: the stock is now -8.8% from the 52-week high but has appreciated +18.0% over the prior 30 days and +18.7% over the prior 90 days. His cross-ticker track record shows 3 prior sells with an average 90-day return of +6.8%, reflecting a 66.67% well-timed rate; however, at RARE specifically, his prior 3 sells were split—two exhibits negative 90-day returns (-6.8%, -2.5%) indicating well-timed sales, while one posted a strong +29.6% 90-day return, indicating poor timing. The company reported $147.0M revenue in the latest quarter with annual revenue growth of +19.5%, but remains unprofitable with -$131.6M net income over its most recent full fiscal year. The sale is modest relative to his total holdings and does not necessarily signal alarm, but the mixed historical timing pattern at this ticker and the company's continued unprofitability warrant monitoring.